List of Xtandi drug patents

Xtandi is owned by Astellas.

Xtandi contains Enzalutamide.

Xtandi has a total of 3 drug patents out of which 0 drug patents have expired.

Xtandi was authorised for market use on 31 August, 2012.

Xtandi is available in capsule;oral dosage forms.

Xtandi can be used as the treatment of patients with metastatic castration-sensitive prostate cancer; treatment of patients with castration-resistant prostate cancer (crpc), treatment of patients with castration-resistant prostate cancer (crpc); the treatment of patients with metastatic castration-sensitive prostate cancer.

The generics of Xtandi are possible to be released after 13 August, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709517 ASTELLAS Diarylhydantoin compounds
Aug, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9126941 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
May, 2026

(3 years from now)

US8183274 ASTELLAS Treatment of hyperproliferative disorders with diarylhydantoin compounds
Aug, 2026

(3 years from now)

Exclusivity Exclusivity Expiration
New Indication (I) Dec 16, 2022

Drugs and Companies using ENZALUTAMIDE ingredient

Market Authorisation Date: 31 August, 2012

Treatment: The treatment of patients with metastatic castration-sensitive prostate cancer; Treatment of patients with castration-resistant prostate cancer (crpc)

Dosage: CAPSULE;ORAL

How can I launch a generic of XTANDI before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in